FOLH1 and posterior cortical atrophy: Since veliparib is the PARPi with the weakest ‘PARP-trapping’ potency, our results, although minimal, could indicate that PCa cell survival after treatment of [177Lu]Lu-PSMA-I&T is not hampered by PARP-trapping [19].